Proton and photon radiotherapy in stage III NSCLC: effects on hematological toxicity and adjuvant immune therapy

The standard-of-care for fit patients with unresectable stage III NSCLC is concurrent chemo-radiation (CCRT) with a radiation dose of 60 Gray (Gy) in 2 Gy daily fractions followed by adjuvant durvalumab for 12 months. In the PACIFIC study, adjuvant durvalumab led to 5-year overall survival (OS) and progression free survival (PFS) rates of 43% and 33%, respectively1. CCRT is a toxic treatment with acute and late side effects that may also compromise treatment efficacy and survival2. The radiation of primary (bone marrow) and secondary lymphoid organs such as the spleen and lymph nodes may also compromise the immune response3.

Source: Radiotherapy and Oncology - November 21, 2023 Category: Radiology Authors: Francesco Cortiula, Lizza E.L. Hendriks, Robin Wijsman, Ruud Houben, Michelle Steens, Sarah Debakker, Richard Canters, Marco Trovo, Nanna M. Sijtsema, Anne G.H. Niezink, Mirko Unipan, Susanna Urban, Anna Michelotti, Safiye Dursun, Gerben Bootsma, Djoya Ha Tags: Original Article Source Type: research